Novel Technology Enables Encapsulated Cell Therapies Without Triggering Fibrosis

from Cell Culture Dish Podcast · host The Cell Culture Dish

Dr. Paul Wotton, CEO, talks about Sigilon Therapeutics’ discovery platform. The platform combines cell engineering and biocompatible Afibromer™ technology to enable cell therapeutics that do not trigger fibrosis.

Episode metadata supplied by the publisher feed · Published Dec 14, 2017

Embed this episode

Attribution link and audio player

NOW PLAYING

Novel Technology Enables Encapsulated Cell Therapies Without Triggering Fibrosis

0:00 18:12

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Cell Culture Dish Podcast?

This episode is 18 minutes long.

When was this Cell Culture Dish Podcast episode published?

This episode was published on December 14, 2017.

Can I download this Cell Culture Dish Podcast episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!